2.1. Study Design
fatty liver
FATTY LIVER, ADIPOSITY, HEPATIC STEATOSIS
This 12-week randomized, controlled, single-blind, AB/BA crossover pilot study was conducted at Monash Health, Melbourne, Australia. All participants were recruited from outpatient clinics and general practice and screened in our gastroenterology outpatient clinics. All provided signed informed consent. The study was approved by Monash Health Human Research Ethics Committee A (registration number: HREC 12298A, 12 January 2013) and registered at the Australian New Zealand Clinical Trials Registry (registration number: ACTRN12613000935730). Eligible subjects were between 18 and 75 years of age with an ultrasound diagnosis of fatty liver [The primary endpoints were a reduction in hepatic steatosis (determined via transient elastography, controlled attenuation parameter (CAP), and visceral adiposity over the course of the study). All co-authors had access to the study data and have reviewed and approved the final version of the manuscript.